Peptide industry: research, production, and market terminology

The peptide industry includes a wide group of organizations involved in research, manufacturing, pharmaceutical development, laboratory analysis, equipment, and specialized scientific services. Although all these activities are interconnected within the broadly defined peptide supply chain, they do not lead to the same type of products, are not subject to identical requirements, and do not answer the same scientific questions.

A research materials supplier may offer peptides intended for laboratory experiments. A manufacturer can produce peptide material on a specific scale. A contract development and manufacturing organization can develop and execute the peptide manufacturing process for another company. In turn, a pharmaceutical company may investigate whether a peptide-containing drug produces a measurable clinical effect in patients.

Analytical laboratories, equipment manufacturers, reagent suppliers, distributors, contract research organizations, formulation specialists, and other service providers also participate in this ecosystem.

These roles often overlap, but they should not be treated as equivalent.

For example, a peptide manufacturer may demonstrate that it has developed a more efficient synthesis process, while a pharmaceutical company investigates whether a drug improves a specific health outcome in patients. A market analyst, on the other hand, may estimate the revenue generated by one or both of these activities.

These measurements answer different questions:

production ≠ clinical benefit ≠ commercial growth.

None of these elements can automatically replace the others.

Understanding these differences makes it easier to interpret supplier descriptions, corporate communications, conference presentations, manufacturing claims, and market forecasts. It also helps avoid a common mistake: treating the popularity or commercial growth of interest in the word „peptide” as proof that every material or product labeled with this term has the same quality, regulatory status, intended use, or level of scientific support.

Research suppliers, manufacturers and CDMOs

Different companies occupy different places in the supply chain

A research materials supplier offers materials or services intended for experimental work.

His catalog may include:

• single peptide sequences;
• custom peptide synthesis;
• peptide libraries;
• modified peptides;
• analytical reference materials;
• materials used in tests;
• other research products.

Some suppliers manufacture the offered materials themselves.

Others source part or all of their product range from external manufacturers.

Therefore:

A company selling a peptide does not have to be the facility that produced the given batch.

The manufacturer performs specific production operations.

Depending on the organization and the product, they may include:

• peptide synthesis;
• biological expression;
• purification;
• insulation;
• drying;
• analytical tests;
• process control;
• other manufacturing activities.

However, the term „producer” itself conveys relatively little information.

One company may specialize in producing material on a milligram or gram scale for early-stage research.

Inna can produce larger quantities of the active pharmaceutical ingredient.

Yet another may produce both the active substance and perform the formulation or filling of the finished product.

CDMO, or contract development and manufacturing organization, is an organization that provides clients with development and manufacturing services on a contract basis.

Development services may include:

• selection of the production route;
• optimization of synthesis;
• refining a difficult purification process;
• developing analytical methods;
• pollution testing;
• process transfer;
• scaling up;
• performance improvement;
• adapting an existing process to a new plant.

The production phase then involves carrying out the agreed-upon manufacturing operations.

The exact scope of services varies between companies, plants, technologies, and individual contracts.

Therefore:

CDMO describes a business and service model, but does not guarantee that a given organization offers all possible development and manufacturing services.

These terms describe practical business functions.

They do not create a universal quality ranking.

The same organization can also fulfill several roles simultaneously. A company can manufacture some products, distribute others, perform laboratory analyses, and at the same time provide development services to external clients.

Therefore, the boundaries between CMOs, CDMOs, and CROs may partially overlap.

A more useful company description should indicate:

what operation is being performed + on what material + at which plant + at what stage of development.

The production path says more than a general label

Peptides can be produced using various strategies.

They may include:

• chemical synthesis;
• biological expression;
• enzymatic or biocatalytic methods;
• hybrid approaches combining multiple technologies.

The most appropriate method depends, among other things, on:

• sequence lengths;
• amino acid composition;
• modification;
• tendency to aggregate;
• solubilities;
• structural complexity;
• purification difficulties;
• required quantity;
• intended use.

A comparison of chemical synthesis and bacterial expression for selected 20–40-residue polypeptides and miniproteins shows why sequence-dependent properties matter. Difficulties related to aggregation or processing can influence which production route is practical. [1]

However, this study does not establish a universal number of amino acids above which chemical synthesis suddenly becomes inferior to biological production.

Peptide production cannot be reliably reduced to the principle:

„short peptide = chemical synthesis”

and

„long peptide = biological production.

Length matters, but it is only one of many parameters.

The contemporary development of peptide production processes also includes biocatalysis.

A 2026 study described engineered enzymatic cascades utilized in the production of the macrocyclic peptide enlicitide, including fragment coupling and cyclization. The researchers presented a protecting-group-free process that utilizes crystallization instead of chromatography at appropriate stages. [2]

This constitutes evidence regarding a specific manufacturing strategy applied to a specific molecule.

It does not prove, however, that:

• every peptide can be produced using the same enzymatic pathway;
• chromatography can always be eliminated;
• protective groups are always unnecessary;
• The publication concerning the manufacturing process confirms the clinical benefit.

The publication concerning process development answers production questions.

It does not automatically answer therapeutic questions.

When evaluating information on „advanced peptide production technology,” it is more useful to ask:

• What peptide was produced?
• What production method was used?
• Which operations have been changed?
• At what scale was the process carried out?
• What performance was achieved?
• How was the cleanup carried out?
• What pollutants were monitored?
• What analytical results are presented?
• Was the process carried out only once, or multiple times?
• Was this a laboratory scale, a pilot scale, or larger?

The term „advanced peptide technology” alone does not answer any of these questions.

Production capacity, efficiency, and sustainability are different claims

Production communications often feature terms such as:

production capacity, performance, scale, sustainable development, productivity and production volume.

These are related, but not equivalent, concepts.

Production capacity determines how much a given plant or production system can potentially produce under specified assumptions.

Actual annual production may depend on:

• schedule;
• production campaign numbers;
• product type;
• duration of the trial;
• device accessibility;
• performances;
• complexities of purification;
• cleaning requirements;
• product releases by quality control;
• supply chain constraints;
• market demand.

Therefore, the theoretical capacity of the devices does not necessarily correspond to the amount of peptide that the facility actually supplies per year as a released product.

Also, „efficiency” can mean a few different things.

The process can become more efficient by:

• fewer synthesis steps;
• increasing the yield;
• reduction of solvent consumption;
• reduction of reagent consumption;
• shortening the production time;
• simplification of purification;
• waste reduction;
• increasing throughput;
• reduction in the number of failed processes.

Improving one metric does not automatically mean improving all the others.

One of the analyses evaluated 40 peptide manufacturing processes from 14 companies, using the process mass intensity (PMI) metric to study material consumption during synthesis, purification, and isolation. [3]

PMI relates the mass of materials used to the mass of the product obtained.

The study therefore provides a quantitative basis for discussing resource consumption and opportunities for improving production.

However, it does not measure patient treatment outcomes.

PMI should also not be treated as a full environmental life cycle assessment.

Environmental assessment may also include:

• energy consumption;
• waste processing;
• properties of solvents;
• emissions;
• water consumption;
• sources of raw materials;
• further environmental impact.

From a commercial perspective, peptide companies can therefore distinguish themselves by:

• process reliability;
• technical knowledge;
• scalability options;
• analytical capabilities;
• efficient resource utilization;
• pollution control;
• production flexibility;
• production capacity.

These can be significant industrial achievements without providing evidence that the peptide itself treats a specific disease.

Peptide APIs vs. finished drugs

API is the active substance, not the entire medicine

API, which stands for active pharmaceutical ingredient, is a substance intended for use in pharmaceutical manufacturing that becomes the active ingredient of a drug.

European Medicines Agency terminology distinguishes the active substance from other elements of pharmaceutical manufacturing. [4]

A peptide API therefore means a peptide acting as an active pharmaceutical ingredient.

Not just any peptide delivered in a larger quantity is one.

This distinction matters because the term „bulk peptide” can refer to materials produced for very different purposes.

The finished medicinal product contains the active substance in a specific pharmaceutical product.

Depending on the product, this may include:

• excipients;
• buffers;
• stabilizers;
• preservatives;
• a specific pharmaceutical form;
• delivery system;
• primary packaging system;
• marking;
• product-specific production;
• stability control;
• microbiological requirements;
• return-to-work medical examinations.

The same active ingredient can potentially occur in different formulations.

These formulations may behave differently.

Therefore:

API identity ≠ finished product properties.

For example, an analytical result confirming the molecular weight of a peptide does not determine how a tablet containing that peptide behaves.

Similarly, the purity result of the starting material does not confirm the stability, sterility, microbiological quality, dissolution, or other properties of the subsequent finished product.

These are various materials at different stages of production.

Each stage requires answering its own scientific questions.

Quality must be evaluated at the appropriate stage

The word „quality” encompasses several different properties.

The identity answers the question:

Is this an intended substance?

Purity answers the question:

What other detectable components are present in the sample according to a specific analytical method?

The quantity or content answers the question:

How much of the intended substance is in the sample?

Stability answers the question:

How do important properties change over time under certain conditions?

The evaluation of the finished product may additionally include:

• the action of the formulation;
• dissolving;
• the supply of substances;
• sterility, if applicable;
• solid particles;
• compliance with the packaging;
• microbiological properties;
• other specific characteristics of the product.

The study of synthetic oxytocin used liquid chromatography combined with high-resolution mass spectrometry to identify structurally related peptide impurities and to more accurately quantify them.[5]

This shows why structurally related relationships can be important in analysis.

The sample may contain the intended peptide and the peptide impurities associated with it that require precise separation and identification.

However, the study does not mean that every peptide product has the same contamination profile.

Similarly, in the comparative study of GLP-1 products, 16 samples of semaglutide in injectable form, eight samples of oral semaglutide, and two samples of liraglutide in injectable form were analyzed together with the reference products. [6]

The researchers described differences, among others, in the following areas:

• pollution;
• content;
• dissolving;
• behavior associated with the formation of fibrils.

Part of the immunogenicity assessments were computer-based predictions.

Importantly, the authors noted that the clinical consequences of the observed differences remain unknown and require clinical studies.[6]

This distinction is crucial:

analytical difference ≠ clinically demonstrated difference.

The analytical results can serve as the basis for further research.

They do not automatically indicate differences in safety or effectiveness in patients.

At the same time:

The absence of a difference detected in one analytical test ≠ demonstrated equivalence of all relevant properties.

Samples of products evaluated in a single study should not be automatically considered representative of each producer, country, supplier, or market.

More about the distinction between identity, purity, content, and the scope of various analytical methods is discussed in a separate guide. Purity of peptides and laboratory tests.

The certificate provides information about the sample and the specific tests performed.

The Certificate of Analysis, or COA, can provide valuable information if it clearly identifies:

• the party;
• a sample;
• conducted tests;
• analytical methods;
• specifications;
• obtained results.

Its evidentiary value depends on the relationship between:

the sample under examination

a

the material that is being delivered or discussed.

The percentage value determined as „purity” must therefore be interpreted according to the method by which it was obtained.

For example, the chromatographic purity percentage can describe the relative percentage of pixel areas detected in a specific chromatographic method.

This does not necessarily mean:

„99% of the total powder mass is intended peptide.”.

These are different measurements.

Questions regarding:

• molecular identity;
• related peptide pollutants;
• quantitative content;
• residual substances;
• water;
• antimicrobial agents;
• other properties of the sample

They may require the use of additional analytical methods.

The study of oxytocin shows why related peptide pollutants and quantitative measurements may require detailed analytical characterization.[5]

The certificate itself does not transform the research material into a ready-made pharmaceutical drug.

Similarly:

The scientific publication regarding the molecule X does not confirm the quality of the independent batch sold under the name X.

Therefore, it is necessary to distinguish three levels of evidence:

evidence regarding the molecule → evidence regarding a specific batch → evidence regarding the finished product.

How do market reports define their scope?

„The ”peptide market” is not a standardized category

The term „peptides market” is precise, but it can describe very different types of business activities.

One report may include peptide drugs.

Another might focus on the equipment and reagents for synthesis.

The next one may measure the value of contract manufacturing services.

Another could include peptide cosmetic ingredients.

Another one, however, may include consumer products containing peptides.

The values of such markets can vary significantly, as they do not necessarily relate to the same type of activity.

For example, the public description of the peptide synthesis market provided by Grand View Research includes categories such as:

• apparatus;
• reagents and consumables;
• services;
• production technologies;
• applications;
• types of customers. [7]

This defines the market related to products and services concerning peptide synthesis.

The description of the peptide therapy market by the same publisher uses different boundaries, including therapeutic products and categories such as:

• disease areas;
• routes of delivery;
• innovative and generic products;
• production models. [8]

These are essentially different economic boundaries.

Public pages show how the publisher defines the individual markets.

They should not be treated as independent audits or clinical evidence.

Only the first two examples correspond directly to the materials cited by the publisher. [7] [8]

The others illustrate other possible market boundaries, the definition of which would have to be verified in a specific report.

Before comparing numbers, the definitions must be compared.

Before comparing the two estimates regarding the peptide market, it is worth answering a few questions.

Product limit:

Which molecules, formulations, devices, services, or consumer categories have been included?

Transaction limit:

Does the report count sales of ingredients, revenue from manufacturing services, wholesale transactions, or sales of finished products?

Geographical boundary:

Does the location mean the place of production, the company headquarters, the location of the customer, or the place of sale of the final product?

Time limit:

Do the values represent historical data, estimates for the current year, or forecasts?

Units:

Does the report use revenue, kilograms of produced material, the number of units sold, the number of contracts, or some other indicator?

Financial basis:

In which currency are the data provided? How have exchange rates been taken into account? Are the values nominal or adjusted for inflation?

Methodology:

What primary sources, surveys, models, assumptions, exclusions, and extrapolations were used to prepare the estimate?

The publicly available summary may not contain information sufficient to answer all of these questions.

In such a case, the uncertainty should remain visible.

A very precise number does not compensate for an unclear definition of the market.

Attention to double counting in the supply chain

The peptide supply chain can involve many commercial transactions involving the same end product.

For example:

reactant supplier → peptide manufacturer → API recipient → pharmaceutical manufacturer → distributor → sale of the final product.

Each of these transactions can generate revenue.

However, adding all these revenues does not necessarily lead to a meaningful estimate of the final spending of consumers or the healthcare system.

The economic value of earlier stages of the chain may already be factored into the prices of later products.

This creates the possibility of double counting.

Therefore, it is necessary to distinguish:

economic activity at many stages of the supply chain

from

sales in the final market.

These are two different indicators.

The growth rate is a calculation, not an explanation

The CAGR, or cumulative annual growth rate, is a mathematical indicator that combines the initial and final values over a given period.

It smooths the transition to an equivalent annual growth rate.

That doesn't mean that the market actually grew at exactly the same percentage every year.

If the hypothetical market increases from 100 to 150 units over five years, its CAGR will be approximately 8.45%.

This calculation does not, however, explain why the market rose.

Possible causes include:

• price increase;
• more products sold;
• the appearance of new products;
• entry into new geographic markets;
• change in the definition of the market;
• acquisitions;
• inflation;
• a combination of several factors.

If the final value is a forecast, the CAGR also does not prove that the expected market size will actually be achieved.

The forecasts depend on assumptions regarding, among other things:

• success in product development;
• regulatory events;
• competition;
• production capacity;
• prices;
• refund;
• the level of product utilization;
• demand.

Trust in the forecast should therefore come from the quality of the assumptions and the source data, not from the number of places after the decimal point.

The scientific publication may also include economic forecasts.

In a review and financial analysis of peptide neoantigen vaccines against triple negative breast cancer, production and financial scenarios were modeled in the United Kingdom.[9]

The results depended on the assumptions regarding production and financing, while the therapeutic effectiveness remained uncertain.

Such analyses can be useful in assessing feasibility.

However, they are not commercially observed results.

They also do not replace clinical efficacy studies.

Revenue, production volume and clinical application can vary independently

Revenue and the physical quantity of a product are different measures.

Revenue can increase, even if the physical quantity of sold material remains relatively stable, if prices rise.

Physical production can grow faster than revenue if prices fall.

A small amount of pharmaceutical peptide with a high value can generate greater revenue than a much larger amount of material with a lower value.

Similarly:

Production capacity ≠ patient access.

The expansion of the factory could increase the potential for production without showing how many patients will receive a specific drug.

The same goes for:

The number of research products ≠ the number of peptides clinically validated.

The provider may offer hundreds or thousands of sequences that do not have a comparable level of biological or clinical evidence.

When describing the growth of the industry, it is therefore necessary to accurately name the measured parameter instead of replacing it with broad statements such as:

„peptides are taking over medicine”.

Scientific conferences and sources of evidence

Conferences are places for presenting evidence, not a substitute for it

Conferences dedicated to peptides can present:

• new synthesis techniques;
• analytical methods;
• production processes;
• structural studies;
• biological results;
• calculation methods;
• clinical trials;
• scientific cooperation.

Professional scientific societies can also make educational materials available and provide access to the research environment.

The American Peptide Society describes itself, for example, as a scientific and educational organization and provides information about publications, conference materials, and symposiums related to peptides.[10]

However, not every element presented at the conference has the same evidentiary status.

The conference program may include:

• invited scientific lectures;
• selected or reviewed abstracts;
• poster presentations;
• Preliminary results of the research;
• presentations of companies;
• commercial workshops;
• educational sessions.

They should not be automatically treated as equivalent.

The conference abstract may contain too little information to assess:

• inspections;
• randomization;
• exclusions;
• statistical methods;
• completeness of reporting results;
• deviations from the original protocol.

The term „peptide world congress” should therefore be treated as a name or search phrase, rather than as a scientific quality certificate.

More important questions are:

• What event?
• Who organized it?
• Who presented the study?
• What exactly was presented?
• Is an abstract available?
• Was the full study later published?
• What methods were used?
• What data supports the stated claim?

The impressive title of the conference does not imply that every presentation was subjected to identical scientific evaluation.

The source should correspond to the type of question

Different sources of evidence answer different questions.

This principle can be summarized simply:

For production claims, use production evidence; for material claims—analytical evidence; for clinical claims—clinical evidence; and for market claims—market methodology.

The type of publication also matters.

The review article organizes the existing evidence. Its conclusions depend on which studies were included, how they were selected, and how the limitations of the studies were assessed.

The original study provides new data, but it may still be:

• narrow;
• preliminary;
• statistically insufficient;
• specific to a particular context;
• difficult to generalize.

The scientific review increases the level of substantive control, but does not eliminate all limitations.

In screening studies, distinguishing between the discovery of an interesting sequence itself and its subsequent validation is also particularly important. This issue is discussed in more detail in the guide to screening. Peptide libraries, screening and sequence design.

Industrial funding is a context, not an automatic verdict

The involvement of the industry in peptide research can be of great scientific importance.

Commercial organizations often have access to:

• specialized production equipment;
• by their own processes;
• experience in large-scale production;
• analytical infrastructure;
• specialized technical knowledge,

whose reproduction in academic laboratories can be difficult.

At the same time, research of commercial significance may involve financial interests.

Readers should therefore pay attention to:

• sources of funding;
• affiliations of the authors;
• conflict of interests;
• the research project;
• methods;
• the availability of results;
• independent confirmation of the results.

The correct reaction is neither:

„the industry-funded study is false,”,

Nor:

„since it has been published, it must be undeniably true.”.

The most important question is whether the conclusion actually stems from the measurements performed.

The demonstration of an improved production process, funded by the manufacturer, can still serve as valuable evidence regarding production.

However, the boundary of such evidence remains the same:

The demonstration of the process provides information about the process — it does not automatically confirm clinical efficacy.

Why is market growth not a clinical evidence?

Commercial demand and biological benefit answer other questions

The growth of the market measures economic activity within certain limits.

Clinical evidence, on the other hand, assesses whether a given intervention causes certain benefits and harms in humans.

These are different questions.

Demand may increase due to:

• effective products;
• greater awareness;
• extensions of indications;
• marketing;
• price changes;
• investor interests;
• speculation;
• more accessibility;
• a combination of several factors.

Therefore:

Commercial popularity does not confirm biological effectiveness.

A breakthrough in production could make it possible to produce a given molecule more easily, cheaply, or more reliably.

However, it does not prove that the molecule improves clinical outcomes.

Similarly, a positive clinical trial of a specific peptide drug does not confirm efficacy:

• other peptide sequences;
• research materials;
• cosmetic ingredients;
• supplements;
• consumer products

just because they are all described as peptides.

A well-founded clinical claim should specify:

• intervention;
• formulation;
• the studied population;
• comparator;
• final point;
• duration;
• the magnitude of the effect;
• uncertainty;
• adverse effects.

None of these elements can be inferred from the percentage growth of the market.

Informal market terminology requires special caution

Terms used on the internet do not always correspond to formal scientific or regulatory classifications.

„The ”supermarket peptide” is a commercial metaphor.

This may suggest that the seller has a very wide catalog.

However, he does not confirm:

• control over production;
• analytical reliability;
• the party’s identity;
• suitability for research;
• pharmaceutical status;
• clinical evidence.

Similarly, „grey peptide market” or „gray peptide market” are descriptive terms, not a single commonly standardized legal category.

Their meaning may vary depending on the author, the jurisdiction, the product, and the context.

The 2026 narrative review discussed digital promotion, uncertain product traceability, and quality issues related to the unregulated use of peptides.[11]

It provides an overview of the reported problems.

However, it does not specify:

• the exact size of such a market;
• frequency of occurrence of quality problems;
• the legal status of each transaction;
• whether every salesperson is exposed to the same risk.

These distinctions lead to a broader principle of evaluating evidence:

The online offer does not confirm the composition of the product.

The purity result does not confirm the clinical benefit.

The biological mechanism does not confirm the properties of an independent batch of commercial product.

The market demand does not confirm the therapeutic efficacy.

The most useful description of the peptide industry should therefore explain:

what was produced, what was measured, what evidence supports the given claim and where does the scope of this evidence end.

How to critically read claims regarding the peptide industry?

A practical way to evaluate industry information is to first determine what kind of claim is being presented.

If a company reports an increase in production capacity, one should ask what equipment or production capabilities have been added and whether the number given refers to theoretical capacity or actual production.

If a company reports an improvement in production efficiency, it is worth checking which parameter has improved: productivity, time, solvent consumption, PMI, difficulty of cleaning, or another indicator.

If the supplier claims „high purity”, it is necessary to determine which analytical method generated this value and what exactly the percentage indicated means.

If the report states that the peptide market is growing rapidly, the market boundaries, geographic scope, period analyzed, revenue definition, and forecast assumptions should be identified.

If a promising peptide is presented at the conference, it must be determined whether the information comes from computer modeling, laboratory experiments, animal studies, preliminary data on humans, or an completed clinical trial.

If the manufacturer describes „new peptide technology”, it is necessary to determine whether the claim relates to synthesis, purification, analytical testing, formulation, delivery of the substance, or clinical activity.

This approach prevents the merging of different types of evidence into a single broad narrative.

Frequently asked questions

1. What do CDMO peptides mean?

CDMO is an organization that provides contract services related to the development and production of peptides to clients. Depending on the company and the project, these services may include choosing a synthesis route, optimizing the process, developing purification methods, developing analytical methods, scaling up the process, transferring the process, and production. Studies comparing chemical synthesis with bacterial expression show why development decisions may depend on a specific peptide rather than a single universal production method. [1] However, the CDMO acronym itself does not specify all the services, technologies, production scales, or capabilities of a given facility. It should be treated as a description of a business model and then verified by examining the actual scope of services.

2. Can peptide market forecasts be directly compared?

Usually not, until their definitions are reviewed. The peptide synthesis market may include equipment, reagents, consumables, and services, whereas the peptide therapy market concerns a different set of products and transactions.[7][8] Even reports with similar titles may differ in geographic scope, forecast years, currency, product definitions, assumptions regarding inflation, and methodology. Public summaries may also omit important methodological details. Therefore, comparisons should be made between values referring to similarly defined markets and any unresolved differences clearly indicated.

3. Is the peptide supplier always its manufacturer?

No. The supplier can either produce the peptide itself or obtain it from another organization. The supplier and the manufacturer describe different functions, even if one company performs both roles. Analytical studies show why the characteristics of a specific material matter, but scientific publication cannot confirm the supply chain or the quality of an independent catalog product. [5] The name of the company visible in the store does not therefore establish on its own which plant produced the given batch. The relationship with the manufacturer, traceability, batch documentation, intended use and appropriate analytical evidence must be evaluated separately.

4. How is CDMO different from CMO and CRO?

CDMO usually combines development with production; the CMO focuses on contract manufacturing, whereas the CRO primarily provides research services on behalf of clients. In practice, however, the scope of services can overlap considerably. Research into peptide production processes may include development work, such as selecting or refining the production route before routine production begins. [2] However, the company’s own acronym does not specify the scope of a specific project. It is more useful to determine what activities have actually been contracted and performed.

5. Is the peptide API the same as the finished drug?

No. Peptide APIs are active substances used in pharmaceutical production, whereas a finished drug is a specific pharmaceutical product containing that substance along with the formulation and properties required for the final product form. [4] A comparative study of GLP-1 products shows that finished products may require evaluation of such characteristics as content, impurities, dissolution, and fibril formation-related properties. [6] The study did not establish the clinical consequences of any observed differences. The API characterization and evaluation of the finished product should therefore be treated as related but separate stages.

6. Does the high percentage of peptide purity confirm the pharmaceutical quality?

No. The purity percentage only answers the question defined by the analytical method and the calculation method used to determine the result. It does not automatically confirm the quantitative content of the peptide, its identity, all possible impurities, stability, sterility, or the activity of the finished product. Studies of synthetic oxytocin required the detailed identification and structural characterization of peptide impurities, showing why a single percentage value may only represent part of the picture. [5] The significance of the purity result also depends on the sample collection and its identity. Therefore, before drawing broader conclusions, it is necessary to verify the material, the method used, and the scope of the study.

7. Does the term „research use only” confirm its usefulness for human use?

No. Labeling a material as intended solely for research does not constitute evidence that it is suitable for human use. Experimental materials and finished pharmaceutical products are associated with different questions regarding quality, production, regulation, and clinical evidence. A narrative review of the unregulated use of peptides discussed issues related to product identity and quality, but did not assess each supplier or determine the frequency of such issues across the market. [11] The „research use only” labeling should therefore be considered a declared intended use of the material, not evidence of safety, efficacy, or suitability for human use.

8. Do all commercial peptides form by a solid-phase synthesis method?

No. Peptide production can involve solid-phase synthesis, other chemical methods, biological expression, enzymatic processes, or combinations of different approaches. Studies comparing chemical synthesis with bacterial expression show sequence-dependent tradeoffs, whereas the enlicitide study is an example of the use of a modified bioconversion process. [1] [2] None of these studies indicate one method as universally best. Production information is therefore more useful when it specifies a specific route of production, a molecule, scale, yield, purification requirements, and appropriate analytical data.

9. Does a larger production facility guarantee better quality?

No. The size of the plant and the nominal production capacity do not determine the quality of a single batch. Quality depends on the proper production process, control, material characteristics, the method of sampling, analytical testing, and other product-specific factors. Comparative studies of products show that many properties may require evaluation, not just one general parameter. [6] This study did not analyze the relationship between plant size and product quality and cannot confirm such a relationship. Therefore, production capacity and quality should be treated as separate statements.

10. Does a lower PMI mean that the drug works better?

No. Lower process mass intensity means less material consumption per unit of product within that specific indicator. The analysis of 40 peptide production processes used PMI to assess the efficiency of resource utilization and identify opportunities for improvement in production. [3] It did not measure therapeutic effects. PMI is also not a complete life cycle environmental analysis. The production process can become more resource-efficient without any change in the biological or clinical activity of the drug.

11. Can market revenues grow without increasing the volume of peptides sold?

Yes. Revenues can increase due to higher prices, changes in product structure, or an increase in the share of higher-value categories, even if the total mass of peptides sold changes little. Revenue and physical production volume are separate indicators. The cited descriptions of market reports also show that categories included in the peptide synthesis market and the peptide therapy market may differ. [7] [8] Without data on price, quantity, product structure, and market boundaries, just an increase in revenue alone cannot explain its cause.

12. What does the CAGR say about the peptide market?

The CAGR describes a constant annual rate that mathematically combines the initial value with the final value over a specified period of time. It smooths out changes over that period and does not represent the actual growth achieved in each year. Economic scenario studies regarding the production of peptide vaccines show how strongly forecasts can depend on the assumptions made, although they are not a general forecast for the entire peptide market. [9] The CAGR therefore does not explain the causes of the growth and does not guarantee the achievement of the projected final value. The dates, scope, assumptions, and methodology remain important.

13. Why shouldn’t we simply add the market value of peptide APIs and finished drugs?

This should not be done automatically, because the same supply chain can generate revenue at many stages. The API is used in the finished product, so part of the value from the previous stage may already be included in the revenue from the sale of the final product. [4] Whether the two market reports partially overlap depends on the exact accounting principles and market definitions. Adding value without examining these boundaries can lead to double counting. First, it must be determined whether end sales, production activity at the previous stage, or the sum of transactions across many parts of the supply chain are being measured.

14. Is the presentation of the peptide at the conference a strong clinical evidence?

It may represent an important clinical study, but the strength of the evidence depends on the study itself, not on the fact of presenting it at a conference. Scientific societies create valuable forums for symposia, publications, and the exchange of results, but participation in a conference does not confirm the quality of any individual claim.[10] Abstracts may omit important information regarding methods, controls, exclusions, statistical analyses, or full results. Therefore, it is important to access the full study and distinguish preliminary conference reports from those that are fully described and capable of evaluating the results.

15. What does „grey peptide market” mean?

„The ”grey peptide market„ or ”gray peptide market” is a descriptive term commonly used in reference to loosely defined supply channels operating outside conventional or clearly documented systems. It is not a single commonly standardized scientific or legal category. The literature on the unregulated use of peptides described problems related to online promotion, product identity, quality, and traceability. [11] However, a narrative review cannot determine the status of each vendor, product, transaction, or jurisdiction. Therefore, the term should be used with caution and clearly specify a specific regulatory, quality, or supply chain-related problem.

16. Is the „peptide supermarket” a recognized quality category?

No. „Supermarket peptides” is a commercial or marketing term, not a scientific, analytical, production, or regulatory quality classification. A large catalog indicates the breadth of the offering, but does not confirm the identity, purity, content, traceability, or properties of a particular product. Analytical studies show that these characteristics require real measurements. [5] The size of the catalog also does not confirm that the seller has produced each product offered independently. The term should therefore be treated as a commercial language, and evidence regarding individual materials should be evaluated separately.

17. What evidence is needed to support a clinical claim regarding the peptide?

Clinical claims require data from human studies relating to a specific peptide intervention, formulation, population, comparator, outcome, and follow-up time. Manufacturing data, molecular mechanisms, analytical characterization, animal studies, and market growth can provide valuable information, but none of these elements alone can confirm the benefits to patients. In the GLP-1 product comparison study, the authors explicitly left the clinical significance of observed analytical differences unresolved. [6] Even positive data regarding a single formulation or indication should not be automatically generalized to others.

18. Does the company's production expansion mean an increase in demand for its peptide medicines?

Not necessarily. Plant expansion may result from anticipated future demand, new customers, business diversification, strategic investments, the need to increase redundancy, the implementation of new technologies, or plans regarding products still in development. Information about increased production capacity describes the infrastructure or production potential, unless actual production and sales data are also presented. Therefore, they should not be automatically interpreted as evidence of increased clinical use or a confirmed therapeutic benefit.

19. Can the COA of the research provider confirm that the product is a pharmaceutical drug?

No. The analysis certificate can provide analytical information about a specific batch, but the status of a pharmaceutical product requires more than a result regarding purity or identity. The COA should be interpreted in relation to the sample, methods, specifications, and results that actually document it. Peptides contamination studies show why the importance of many analytical properties can be significant. [5] The certificate may support the claim regarding the conducted studies, but it does not independently confirm the entire production process, formulation, regulatory status, or clinical evidence related to the finished drug.

20. Why do peptide market reports give different values?

Reports can present different values because they define the market differently. One may include peptide therapies, another equipment and services related to synthesis, a third contract production, and a fourth a narrower product or geographic category. [7] [8] Reports can also differ in the base year, the forecast period, currency conversions, the way inflation is taken into account, the data sources, the assumptions, and the modeling methodology. Therefore, the difference between the two market values does not automatically mean that one report is wrong. First, one must compare their boundaries and methods.

Limitations in the interpretation of information about the peptide industry

When analyzing information related to the peptide industry, it is important to keep in mind several recurring limitations.

First, industry terminology is not completely standardized across all companies and contexts. Suppliers, manufacturers, CMOs, CDMOs, and CROs describe useful business functions, but the actual scope of services may partially overlap.

Second, production evidence should not be transformed into clinical evidence. Improvement in productivity, PMI, purification, production capacity, or production technology describes industrial properties, not benefits for patients.[2][3]

Thirdly, analytical evidence relates to specific material. The result obtained for a single sample, batch, or finished product does not automatically confirm the properties of other products labeled with the same molecule. [5] [6]

Fourthly, market estimates depend on the definition. The market for peptide synthesis and the market for peptide therapeutics may essentially encompass different types of commercial activity. [7] [8]

Fifthly, forecasts depend on models and do not constitute observed facts regarding the future. CAGR and future market values are based on assumptions that may change.

Sixthly, the visibility at the conference does not determine the strength of the evidence. What matters most remain the design of the study, the methods, the data, and the way of reporting. [10]

Seventhly, informal terms such as „peptide supermarket” and „grey peptide market” are not standardized scientific quality categories. Their meaning must be defined in a specific context. [11]

Finally, commercial, production, analytical, and clinical evidence should remain related to exactly the question that the data source can answer.

Summary

The peptide industry is not a single unified market.

This is a combined ecosystem that includes:

• suppliers of research materials;
• manufacturers of peptides;
• distributors;
• CRO;
• CMO;
• CDMO;
• companies developing pharmaceutical products;
• analytical laboratories;
• manufacturers of equipment;
• suppliers of reagents;
• other specialized service providers.

Understanding the differences between these roles is important because the same word — „peptide” — can refer to materials and products that are at completely different stages.

For readers who want to start from the basics of chemistry and biology, a guide explaining the concepts can be a starting point. what peptides are, how they work, and how they are classified.

The research peptide is not automatically a pharmaceutical API.

Peptide APIs are not the same as a finished drug.

The supplier does not have to be the manufacturer.

The term CDMO does not describe all the possibilities of each facility.

The breakthrough in production does not prove clinical effectiveness.

The purity percentage does not describe all aspects of quality.

The market forecast does not confirm the biological benefits.

A conference presentation does not become strong clinical evidence solely because it is presented during a prestigious event.

The same division should be applied when analyzing market data.

The market for peptide synthesis may include equipment, reagents, consumables, and services, whereas the market for peptide therapeutics concerns therapeutic products.[7][8]

Their values should therefore not be compared or summed up without first determining exactly what each of the reports covers.

Similarly, revenue, production volume, production capacity, and clinical application can change independently.

The most reliable way to interpret information about the peptide industry is to ask four questions:

What exactly is being discussed?

What exactly was measured?

What source supports this claim?

Where does the scope of these proofs end?

This approach allows for proper evaluation of actual progress in peptide synthesis, production, laboratory analysis, pharmaceutical development, and commercialization without extending conclusions beyond what has actually been demonstrated.

Disclaimer

The article is purely educational and scientifically informative in nature. It explains the terminology and types of evidence used in discussions regarding suppliers of research materials, the production of peptides, APIs, finished pharmaceutical products, CDMOs, market reports, analytical studies, and scientific conferences. It does not constitute medical, investment, regulatory, or purchasing advice and is not a recommendation to use any peptide product. References to companies, markets, production technologies, analytical studies, or product categories are solely intended to clarify terminology and the way evidence is evaluated and should not be interpreted as recommendations. Research materials, pharmaceutical active substances, and finished medicines constitute separate categories, and evidence regarding one of them should not be automatically extrapolated to the others.

References

1. Stráner, P., Taricska, N., Szabó, M., Tóth, G. K., & Perczel, A. (2016). Bacterial expression and/or solid phase peptide synthesis of 20–40 amino acid long polypeptides and miniproteins, the case study of Class B GPCR ligands. Current Protein & Peptide Science, 17(2), 147–155. https://doi.org/10.2174/1389203716666151102105215
2. Klapars, A., Fryszkowska, A., Galanie, S., Ad, O., Aguilera, E. Y., Akporji, N., An, C., Axnanda, S., Ayele, T. M., Ayikpoe, R. S., Barrientos, R. C., Bauerle, M. R., Becker, M. R., Belyk, K. M., Bereznitski, L., Cahn, J. K. B., Soto, K. C., Campeau, L. C., Campos, K. R., … Zhong, W. (2026). Biocatalytic cascades enable the manufacture of the macrocyclic peptide enlicitide. Science, 392(6798), 643–647. https://doi.org/10.1126/science.aed8713
3. Kekessie, I., Wegner, K., Martinez, I., Kopach, M. E., White, T. D., Tom, J. K., Kenworthy, M. N., Gallou, F., Lopez, J., Koenig, S. G., Payne, P. R., Eissler, S., Arumugam, B., Li, C., Mukherjee, S., Isidro-Llobet, A., Ludemann-Hombourger, O., Richardson, P., Kittelmann, J., … van den Bos, L. J. (2024). Process mass intensity (PMI): A holistic analysis of current peptide manufacturing processes informs sustainability in peptide synthesis. Journal of Organic Chemistry, 89(7), 4261–4282. https://doi.org/10.1021/acs.joc.3c01494
4. European Medicines Agency. (n.d.). Glossary. Retrieved September 20, 2026, from Glossary
5. Li, M., Josephs, R. D., Daireaux, A., Choteau, T., Westwood, S., Martos, G., Wielgosz, R. I., & Li, H. (2021). Structural-related peptide impurity identification and accurate quantification for synthetic oxytocin by liquid chromatography-high-resolution mass spectrometry. Analytical and Bioanalytical Chemistry, 413(7), 1861–1870. https://doi.org/10.1007/s00216-021-03154-5
6. Hach, M., Engelund, D. K., Mysling, S., Mogensen, J. E., Schelde, O., Haselmann, K. F., Lamberth, K., Vilhelmsen, T. K., Malmstrøm, J., Højlys-Larsen, K. B., Rasmussen, T. S., Borch-Jensen, J., Mortensen, R. W., Jensen, T. M. T., Kesting, J. R., Catarig, A. M., Asgreen, D. J., Christensen, L., & Staby, A. (2024). Impact of manufacturing process and compounding on properties and quality of follow-on GLP-1 polypeptide drugs. Pharmaceutical Research, 41(10), 1991–2014. https://doi.org/10.1007/s11095-024-03771-6
7. Grand View Research. (n.d.). Peptide synthesis market. Retrieved September 20, 2026, from Peptide synthesis market
8. Grand View Research. (n.d.). Peptide therapeutics market. Retrieved September 20, 2026, from Peptide therapeutics market
9. Novakova, A., Morris, S. A., Vaiarelli, L., & Frank, S. (2025). Manufacturing and financial evaluation of peptide-based neoantigen cancer vaccines for triple-negative breast cancer in the United Kingdom: Opportunities and challenges. Vaccines, 13(2), Article 144. https://doi.org/10.3390/vaccines13020144
10. American Peptide Society. (n.d.). American Peptide Society. Retrieved September 20, 2026, from American Peptide Society
11. Hailu, K. T., Abriha, F. N., Duguma, Y. M., Haddad, R. R., Liyew, T., & Kasagga, A. (2026). Unregulated peptide use in the age of biohacking: Digital promotion, gray-market access, and emerging public health risks. Cureus, 18(6), Article e110657. https://doi.org/10.7759/cureus.110657